Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Foghorn Therapeutics Inc. FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:FHTX)

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

GlobeNewswire 6 days ago

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

GlobeNewswire 10 days ago

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

GlobeNewswire March 26, 2024

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

GlobeNewswire March 7, 2024

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

GlobeNewswire March 5, 2024

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

GlobeNewswire February 8, 2024

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

GlobeNewswire January 8, 2024

Foghorn Therapeutics Announces CFO Departure

GlobeNewswire January 3, 2024
View More News ››

Opinion & Analysis (NDAQ:FHTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:FHTX)

Be the first to post on this bullboard.

Blue Sky Uranium Corp

Blue Sky Uranium Corp

Blue Sky Uranium Corp. is a uranium and vanadium exploration company. The Company is focusing its uranium and vanadium ...
View More »